Barclays analyst Matt Miksic raised the firm’s price target on Medtronic (MDT) to $118 from $116 and keeps an Overweight rating on the shares. The company’s preliminary comments on puts and takes for fiscal 2027 tempered the stock reaction to its solid fiscal Q3 beat, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Medtronic: Sustained Outperformance and Multi‑Year Growth Runway Driven by Cardiovascular and Robotics Pipelines
- Medtronic Earnings Call Highlights Growth and Margin Upside
- Midday Fly By: Warner Bros. reopens Paramount talks
- Morning Movers: Masimo surges, Danaher slumps after $9.9B deal
- Medtronic sees FY26 adjusted revenue $36.1B-$36.2B, consensus $35.98B